Newsletter
News & Events | Applied StemCell
Company News
-
December 04, 2023 9:00 AM Eastern Standard Time MILPITAS, Calif.--Applied StemCell, Inc., a leading CRO/CDMO recognized for its proprietary TARGATT gene editing technology and expertise in stem cells and cell therapy development, is pleased to announce the addition of ...Read more
-
Oct 9, 2023QHP Capital Acquires Applied StemCell
Strategic Financial Sponsor to Support Continued Growth and Market Expansion RALEIGH, NC and MILPITAS, CA, October 9, 2023 – QHP Capital (“QHP”), today announced its acquisition of Applied Stem Cell, Inc. (“ASC” or the “Company”), a leading cell and ...Read more
-
Jun 12, 2023Applied StemCell Inc. partners with CIRM | ASC
Applied StemCell Inc. partners with CIRM to provide clinical-grade iPSCs and access to its proprietary gene editing technologies to accelerate the development of regenerative therapies Milpitas, CA USA, 13 June 2023: Applied StemCell, Inc. (ASC) and the California Institute for ...Read more
-
Aug 29, 2022Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy
Milpitas, California, August 29, 2022 -- Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced ...Read more
-
Milpitas, California, August 3, 2021 -- Applied StemCell, Inc.’s GMP facility is Now Fully Licensed and Ready for Drug Product Manufacturing. Applied StemCell (ASC), a fast-growing Gene & Cell Therapy CRO, today announced that the California Department of Public ...Read more